Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of secukinumab in active non-radiographic axial spondyloarthritis
MOH_2017-03-05_000125Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in non-radiographic axial spondyloarthritis (nr-axSpA) (3 arms), sponsored by Novartis. Primary endpoints: ASAS40 response at week 16 and ASAS40 response at week 52. Started Jun 2016; status: completed.
02
Drugs
secukinumab
03
Conditions
non-radiographic axial spondyloarthritis (nr-axSpA)
Beyond the preview
Go deeper on MOH_2017-03-05_000125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-05_000125.